EA200601803A1 - Пиридилзамещенные порфириновые соединения и способы их применения - Google Patents
Пиридилзамещенные порфириновые соединения и способы их примененияInfo
- Publication number
- EA200601803A1 EA200601803A1 EA200601803A EA200601803A EA200601803A1 EA 200601803 A1 EA200601803 A1 EA 200601803A1 EA 200601803 A EA200601803 A EA 200601803A EA 200601803 A EA200601803 A EA 200601803A EA 200601803 A1 EA200601803 A1 EA 200601803A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pyridyl
- methods
- substituted porphyrin
- resulting
- disease
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000006378 damage Effects 0.000 abstract 3
- -1 porphyrin compounds Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 206010058490 Hyperoxia Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000222 hyperoxic effect Effects 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 239000000203 mixture Chemical class 0.000 abstract 1
- 230000003680 myocardial damage Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
- C07F11/005—Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
Abstract
Настоящее изобретение относится к пиридилзамещенным порфириновым соединениям, композициям, содержащим эффективное количество пиридилзамещенного порфиринового соединения, и к способам лечения или профилактики повреждения, возникающего в результате действия химически активных видов, эректильной дисфункции, являющейся результатом операции, заболевания легких, гипероксии, нейродегенеративного заболевания, заболевания печени, поражения миокарда во время кардиоплегии, воспалительного состояния, повреждения, связанного с реперфузией, ишемического состояния, сердечно-сосудистого заболевания, диабета, диабетического осложнения, опухолей, побочного эффекта, возникающего в результате химиотерапии опухолей, или поражения, вызываемого облучением, и к продлению времени полужизни соединения, подверженного окислению, способам, включающим в себя введение субъекту при необходимости эффективного количества пиридилзамещенного порфиринового соединения.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55755104P | 2004-03-29 | 2004-03-29 | |
US62846504P | 2004-11-16 | 2004-11-16 | |
PCT/US2005/010167 WO2005097123A2 (en) | 2004-03-29 | 2005-03-25 | Pyridyl-substituted porphyrin compounds and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200601803A1 true EA200601803A1 (ru) | 2007-10-26 |
EA010834B1 EA010834B1 (ru) | 2008-12-30 |
Family
ID=35125604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200601803A EA010834B1 (ru) | 2004-03-29 | 2005-03-25 | Пиридилзамещённые порфириновые соединения и способы их применения |
Country Status (11)
Country | Link |
---|---|
US (2) | US7432369B2 (ru) |
EP (1) | EP1740094A4 (ru) |
JP (1) | JP2007530695A (ru) |
KR (1) | KR20060135922A (ru) |
AU (1) | AU2005231336A1 (ru) |
BR (1) | BRPI0509359A (ru) |
CA (1) | CA2561266A1 (ru) |
EA (1) | EA010834B1 (ru) |
IL (1) | IL178331A0 (ru) |
MX (1) | MXPA06011244A (ru) |
WO (1) | WO2005097123A2 (ru) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2397067B (en) * | 2002-12-23 | 2005-05-11 | Destiny Pharma Ltd | Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation |
AU2005231336A1 (en) * | 2004-03-29 | 2005-10-20 | Inotek Pharmaceuticals Corporation | Pyridyl-Substituted Porphyrin Compounds and methods of use thereof |
GB2415372A (en) | 2004-06-23 | 2005-12-28 | Destiny Pharma Ltd | Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent |
CA2622988A1 (en) * | 2005-09-28 | 2007-04-05 | Inotek Pharmaceuticals Corporation | N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof |
KR20080065704A (ko) * | 2005-11-09 | 2008-07-14 | 콤비네이토릭스, 인코포레이티드 | 의학적 이상의 치료 방법들, 조성물들, 및 키트들 |
US20100120738A1 (en) * | 2006-09-11 | 2010-05-13 | Bernard Malfroy-Camine | Anti-apoptotic benzodiazepine receptor ligand inhibitors |
SI2056675T1 (sl) | 2006-10-12 | 2019-08-30 | Galera Labs, Llc | Postopki za zdravljenje oralnega mukozitisa |
KR20080047959A (ko) * | 2006-11-27 | 2008-05-30 | 주식회사 엠디바이오알파 | 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물 |
EP2192899B1 (en) * | 2007-08-28 | 2014-10-01 | Technion Research and Development Foundation, Ltd. | Transition metal complexes of corroles for preventing cardiovascular diseases or disorders |
KR101405823B1 (ko) * | 2007-12-24 | 2014-06-12 | 주식회사 케이티앤지생명과학 | 녹내장의 치료 및 예방을 위한 약제 조성물 |
KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
US20090257999A1 (en) * | 2007-12-31 | 2009-10-15 | Inotek Pharmaceuticals Corporation | Method of preventing contrast-induced nephropathy |
JP5669123B2 (ja) * | 2009-03-17 | 2015-02-12 | 国立大学法人 東京大学 | 発光によるビタミンc検出法及び定量法 |
JP4510929B1 (ja) * | 2009-04-09 | 2010-07-28 | パナソニック株式会社 | テロメラーゼ反応阻害方法およびそれに用いられるテロメラーゼ反応阻害剤 |
CN102006871B (zh) * | 2009-04-09 | 2013-05-22 | 松下电器产业株式会社 | 端粒酶反应的抑制方法 |
US20120135973A1 (en) * | 2010-09-08 | 2012-05-31 | Southern Illinois University Edwardsville | Method for treating chronic pain |
CN103906756B (zh) | 2011-09-26 | 2020-03-03 | 加莱拉实验室有限责任公司 | 用于治疗疾病的方法 |
US9572816B2 (en) | 2012-10-25 | 2017-02-21 | Technion Research And Development Foundation Ltd. | Method of treatment of disease |
WO2015040622A1 (en) * | 2013-09-22 | 2015-03-26 | Laster Brenda | The continuous long-term controlled release of telomerase inhibitors |
US9034596B1 (en) | 2014-04-17 | 2015-05-19 | Kuwait University | Method for fluorescent staining of cellular and intracellular membranes |
WO2019152661A1 (en) * | 2018-01-31 | 2019-08-08 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4822899A (en) | 1985-04-12 | 1989-04-18 | The University Of Michigan | Metallic porphyrin complexes as catalysts in epoxidation reactions |
US5990363A (en) | 1987-01-02 | 1999-11-23 | Sun Company, Inc. | Method for oxidizing alkanes using novel porphyrins synthesized from dipyrromethanes and aldehydes |
US5227405A (en) | 1987-03-31 | 1993-07-13 | Duke University | Superoxide dismutase mimic |
US5223538A (en) | 1987-03-31 | 1993-06-29 | Duke University | Superoxide dismutase mimic |
JPH0338587A (ja) | 1989-07-03 | 1991-02-19 | Doujin Kagaku Kenkyusho:Kk | 酸化反応を触媒する標識化合物 |
US6204259B1 (en) | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
US5994339A (en) | 1993-10-15 | 1999-11-30 | University Of Alabama At Birmingham Research Foundation | Oxidant scavengers |
US6127356A (en) | 1993-10-15 | 2000-10-03 | Duke University | Oxidant scavengers |
US5747026A (en) | 1993-10-15 | 1998-05-05 | University Of Alabama At Birmingham Research Foundation | Antioxidants |
FR2717385B1 (fr) | 1994-03-21 | 1996-04-19 | Oreal | Composition cosmétique contenant en association une superoxyde dismutase et une porphyrine. |
US6245758B1 (en) | 1994-05-13 | 2001-06-12 | Michael K. Stern | Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor |
WO1996009053A1 (en) | 1994-09-20 | 1996-03-28 | Duke University | Oxidoreductase activity of manganic porphyrins |
US6013241A (en) | 1995-01-23 | 2000-01-11 | Schering Aktiengesellschaft | Use of porphyrin-complex or expanded porphyrin-complex compounds as an infarction localization diagnosticum |
AU6031096A (en) | 1995-06-05 | 1996-12-24 | Duke University | Nitrosylated and nitrated superoxide oxidants and reductants |
JPH11509180A (ja) * | 1995-06-07 | 1999-08-17 | デューク・ユニバーシティ | 酸化体脱除剤 |
US6002026A (en) | 1996-07-26 | 1999-12-14 | The Trustees Of Princeton University | Catalytic oxygenation of hydrocarbons by metalloporphyrin and metallosalen complexes |
DE19647640A1 (de) | 1996-11-18 | 1998-05-20 | Basf Ag | Monoverbrückte Porphyrin-Dimere und deren Metallkomplexe, Verfahren zu deren Herstellung sowie katalytische Verfahren unter Verwendung der Metallporphyrinkomplexe |
EP0988037A1 (en) | 1997-02-05 | 2000-03-29 | Board Of Regents, The University Of Texas System | Porphyrin compounds as telomerase inhibitors |
IL135949A0 (en) * | 1997-11-03 | 2001-05-20 | Univ Duke | Substituted porphyrins |
US6194566B1 (en) | 1997-12-02 | 2001-02-27 | Schering Aktiengesellschaft | Process for the production of metalloporphyrin-metal complex conjugates |
US6479477B1 (en) | 1998-04-24 | 2002-11-12 | Duke University | Substituted porphyrins |
IL126953A0 (en) | 1998-11-08 | 1999-09-22 | Yeda Res & Dev | Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives |
BR0007720B1 (pt) | 1999-01-25 | 2014-04-08 | Univ Duke | Porfirinas substituídas e método de proteção de células contra toxicidade induzida por oxidante |
US6448239B1 (en) * | 1999-06-03 | 2002-09-10 | Trustees Of Princeton University | Peroxynitrite decomposition catalysts and methods of use thereof |
AU1087401A (en) | 1999-10-13 | 2001-04-23 | Uab Research Foundation | Metalloporphyrin treatment of neurologic disease |
US20030069281A1 (en) | 2000-06-14 | 2003-04-10 | Irwin Fridovich | Tetrapyrroles |
US6403788B1 (en) | 2000-07-11 | 2002-06-11 | Eukarion, Inc. | Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species |
US6573258B2 (en) | 2000-09-27 | 2003-06-03 | Frontier Scientific, Inc. | Photodynamic porphyrin antimicrobial agents |
AU2002312194B8 (en) * | 2001-06-01 | 2008-05-15 | Aeolus Sciences, Inc. | Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance |
GB0114155D0 (en) | 2001-06-11 | 2001-08-01 | Unilever Plc | Complex for catalytically bleaching a substrate |
US20030086916A1 (en) * | 2001-10-12 | 2003-05-08 | Goligorsky Michael S. | Use of peroxynitrite scavengers or peroxynitrite formation inhibitors that do not diminish nitric oxide synthesis or activity to reverse or prevent premature vascular senescence |
FR2837202B1 (fr) | 2002-03-15 | 2007-08-31 | Centre Nat Rech Scient | Nouveaux derives de porphyrines, leur procede de preparation compositions pharmaceutiques et utilisations |
CN100420689C (zh) * | 2002-04-08 | 2008-09-24 | 巩宪昌 | 带有大取代基的卟啉衍生物、其制备方法及其作为小分子抗氧化剂的应用 |
US6650137B2 (en) * | 2002-04-11 | 2003-11-18 | Daimlerchrysler Corporation | Circuit for monitoring an open collector output circuit with a significant offset |
CA2488500A1 (en) | 2002-06-07 | 2003-12-18 | Duke University | Substituted porphyrins |
EP1718201B1 (en) * | 2004-02-09 | 2016-09-14 | Duke University | Substituted porphyrins |
AU2005231336A1 (en) * | 2004-03-29 | 2005-10-20 | Inotek Pharmaceuticals Corporation | Pyridyl-Substituted Porphyrin Compounds and methods of use thereof |
CA2622988A1 (en) | 2005-09-28 | 2007-04-05 | Inotek Pharmaceuticals Corporation | N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof |
EP1962597A4 (en) | 2005-11-30 | 2008-12-17 | Inotek Pharmaceuticals Corp | PURINE DERIVATIVES AND METHOD OF USE |
-
2005
- 2005-03-25 AU AU2005231336A patent/AU2005231336A1/en not_active Abandoned
- 2005-03-25 JP JP2007506402A patent/JP2007530695A/ja active Pending
- 2005-03-25 MX MXPA06011244A patent/MXPA06011244A/es active IP Right Grant
- 2005-03-25 EA EA200601803A patent/EA010834B1/ru not_active IP Right Cessation
- 2005-03-25 EP EP05732040A patent/EP1740094A4/en not_active Withdrawn
- 2005-03-25 US US11/090,447 patent/US7432369B2/en not_active Expired - Fee Related
- 2005-03-25 CA CA002561266A patent/CA2561266A1/en not_active Abandoned
- 2005-03-25 WO PCT/US2005/010167 patent/WO2005097123A2/en active Application Filing
- 2005-03-25 BR BRPI0509359-7A patent/BRPI0509359A/pt not_active IP Right Cessation
- 2005-03-25 KR KR1020067022445A patent/KR20060135922A/ko not_active Application Discontinuation
-
2006
- 2006-09-27 IL IL178331A patent/IL178331A0/en unknown
-
2007
- 2007-07-19 US US11/880,068 patent/US20080009473A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1740094A4 (en) | 2008-09-03 |
US20060003982A1 (en) | 2006-01-05 |
US7432369B2 (en) | 2008-10-07 |
WO2005097123A3 (en) | 2005-12-22 |
EP1740094A2 (en) | 2007-01-10 |
IL178331A0 (en) | 2007-02-11 |
EA010834B1 (ru) | 2008-12-30 |
CA2561266A1 (en) | 2005-10-20 |
KR20060135922A (ko) | 2006-12-29 |
WO2005097123A2 (en) | 2005-10-20 |
US20080009473A1 (en) | 2008-01-10 |
MXPA06011244A (es) | 2007-04-13 |
BRPI0509359A (pt) | 2007-09-04 |
AU2005231336A1 (en) | 2005-10-20 |
JP2007530695A (ja) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200601803A1 (ru) | Пиридилзамещенные порфириновые соединения и способы их применения | |
WO2007038630A3 (en) | N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof | |
BRPI0607240A2 (pt) | derivados de maleimida, composições farmacêuticas e métodos para tratamento de cáncer | |
SMT201300096B (it) | Inibitori di prolil idrossilasi | |
EA200601558A1 (ru) | Производные изохинолинов и способы их использования | |
NO20074737L (no) | Isokinolinforbindelser og fremgangsmater for anvendelse derav | |
EA200600689A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов raf киназы | |
WO2007125405A3 (en) | Substituted 2-amino-fused heterocyclic compounds | |
EA201170061A1 (ru) | Новые производные фенилимидазола в качестве ингибиторов фермента pde10a | |
EA201200021A1 (ru) | Фунгицидные смеси | |
WO2006120573A3 (en) | Heterocyclic n-oxides as hypoxic selective protein kinase inhibitors | |
AR036597A1 (es) | Derivados de 1h-imidazol que tienen actividad agonista de cb1, agonista parcial de cb1 o antagonista de cb1 | |
EA200901212A1 (ru) | 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний | |
TW200730532A (en) | Camptothecin derivatives as chemoradiosensitizing agents | |
DK1885187T3 (da) | Fremgangsmåde til behandling af lægemiddelresistent cancer | |
EA201001094A1 (ru) | Производные индазола | |
EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
ATE526025T1 (de) | Behandlung metastasierter tumore | |
EA202090959A1 (ru) | Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза | |
Saada et al. | Mono-and di-halogenated histamine, histidine and carnosine derivatives are potent carbonic anhydrase I, II, VII, XII and XIV activators | |
EA202191144A1 (ru) | Состав ингибитора bcl-2 на основе циклодекстрина | |
EA200800788A1 (ru) | Фунгицидные смеси на основе триазолов | |
ATE538105T1 (de) | Substituierte tetrazolverbindungen und ihre verwendung | |
UA90340C2 (ru) | Фунгицидная смесь на основе триазолов, композиция на ее основе и способ борьбы с фитопатогенными грибами | |
EA200800776A1 (ru) | Производные хинолина и применение в качестве противоопухолевых агентов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |